Background: Cancer is one of the chronic diseases with the highest morbidity and mortality worldwide. The preference of alternative therapies in patients with cancer such as Amygdalin has increased, but the extent and nature of the literature regarding this is unknown. Objective: Describe the nature, variety and extent of the literature surrounding the use of Amygdalin in cancer patients. Methodology: Systematic review of scope literature. The MEDLINE bases were consulted through PUBMED, EMBASE, LILACS and gray literature in google scholar. Studies in human or human tissue (in vitro) with any type of cancer, all presentation and routes of administration of Amygdalin were included. Three reviewers (SM, NC and BV) independently screened and extracted data. It was synthesized in: authors, year of publication, country, type of study, sample size, population and type of intervention. Results: Duplicates were removed from 2,402 references. 399 articles are excluded in title and summary screening. Of 216 full articles, 35 were included in the synthesis. Narrative reviews (n=15), experimental in vitro studies (n=12), case reports (n=4), systematic reviews (n=2) and observational (n=2) were reported. The main country to publish was the United States, followed by Germany. Discussion: All evidence surrounding the use of Amygdalin was not recovered. This makes the interpretation and analysis of the data collected more complex. Conclusion: There was no discrepancy among the authors for not recommending the use of Amygdalin as a treatment for cancer patients.